RESUMEN
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases in the developed world, affecting 1-3% of the adult population in Europe. This inflammatory disease can have a marked impact on affected individuals, leading to significant impairment in physical wellbeing and quality of life (QoL). The aim of this study was to investigate the psychosocial impact and financial burden of AD on patients in Ireland. To increase our understanding of the psychosocial and financial aspects of AD disease burden in the Irish population, an online survey was designed. The survey was launched by the Irish Skin Foundation, and included questions focusing on disease severity, disease control, psychosocial impact, interrupted sleep, missed work and school days, and financial cost. The survey showed that the impact of AD on QoL was profound. The survey demonstrated that 85% of adults described interrupted sleep, 70% reported social anxiety, 65% avoid exercise and sports, 52% avoid social activities, 52% avoid sexual intimacy and 43% feel they are depressed as a result of their AD. Approximately one-quarter of those surveyed can spend up to 2300 annually on over-the-counter, prescription and alternative treatments. This study has shown the significant impact AD has on patients living in Ireland. It also highlights that out-of-pocket costs for patients is higher compared with previous studies across European countries.
Asunto(s)
Costo de Enfermedad , Dermatitis Atópica/psicología , Gastos en Salud/estadística & datos numéricos , Adolescente , Adulto , Niño , Preescolar , Dermatitis Atópica/economía , Femenino , Encuestas Epidemiológicas , Humanos , Irlanda , Masculino , Persona de Mediana Edad , Gravedad del Paciente , Calidad de VidaRESUMEN
We review current applications of Big Data in diabetes care and consider the future potential by carrying out a scoping study of the academic literature on Big Data and diabetes care. Healthcare data are being produced at ever-increasing rates, and this information has the potential to transform the provision of diabetes care. Big Data is beginning to have an impact on diabetes care through data research. The use of Big Data for routine clinical care is still a future application. Vast amounts of healthcare data are already being produced, and the key is harnessing these to produce actionable insights. Considerable development work is required to achieve these goals.
Asunto(s)
Macrodatos , Investigación Biomédica , Diabetes Mellitus , Ahorro de Costo , Genómica , Humanos , Procesamiento de Imagen Asistido por Computador , Aprendizaje Automático , Medicina de Precisión , Datos de Salud Recolectados RutinariamenteAsunto(s)
COVID-19/patología , Dermatología/organización & administración , Líneas Directas/estadística & datos numéricos , Enfermedades de la Piel/patología , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/psicología , Fundaciones/organización & administración , Accesibilidad a los Servicios de Salud/tendencias , Líneas Directas/tendencias , Humanos , Irlanda/epidemiología , Rol de la Enfermera , SARS-CoV-2/genética , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/epidemiologíaAsunto(s)
Alopecia/etiología , Alopecia/patología , Neoplasias de la Mama/complicaciones , Cicatriz/patología , Anciano , Alopecia/diagnóstico , Alopecia/tratamiento farmacológico , Anastrozol/uso terapéutico , Inhibidores de la Aromatasa/uso terapéutico , Biopsia , Conservadores de la Densidad Ósea/uso terapéutico , Neoplasias de la Mama/secundario , Diagnóstico Diferencial , Quimioterapia Combinada , Eritema/patología , Femenino , Humanos , Inmunohistoquímica/métodos , Metástasis de la Neoplasia/patología , Piperazinas/uso terapéutico , Inhibidores de Proteínas Quinasas/uso terapéutico , Piridinas/uso terapéutico , Cuero Cabelludo/patología , Telangiectasia/patología , Ácido Zoledrónico/uso terapéuticoAsunto(s)
Acrodermatitis/diagnóstico , Proteínas de Transporte de Catión/genética , Zinc/administración & dosificación , Zinc/deficiencia , Acrodermatitis/sangre , Acrodermatitis/tratamiento farmacológico , Acrodermatitis/genética , Administración Cutánea , Administración Intravenosa , Betametasona/administración & dosificación , Proteínas de Transporte de Catión/metabolismo , Análisis Mutacional de ADN , Quimioterapia Combinada/métodos , Femenino , Floxacilina/administración & dosificación , Pie , Mutación del Sistema de Lectura , Humanos , Recurrencia , Brote de los Síntomas , Adulto Joven , Zinc/sangre , Zinc/metabolismoRESUMEN
The association of linear IgA disease (LAD) with ulcerative colitis (UC) is well documented. One hypothesis for the association proposes immune exposure to autoantigens present in the colon, and subsequent targeting of these autoantigens in the skin. There are variable reports on the effect of bowel surgery on skin disease in such patients. We report a patient with LAD and UC who required colectomy to control her UC, but whose skin disease failed to resolve following surgery. A literature review revealed that in reported cases of this association, proctocolectomy has resulted in remission of skin disease in all cases where it has been performed, in contrast to variable results seen in cases where colectomy alone was performed.
Asunto(s)
Colectomía , Colitis Ulcerosa/cirugía , Dermatosis Bullosa IgA Lineal/etiología , Colitis Ulcerosa/complicaciones , Femenino , Humanos , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
AIMS: To synthesize evidence relating to comparisons between patient-generated blood glucose records and meter memory in diabetes and to identify any predictors of agreement. METHODS: A systematic literature search was performed to identify articles comparing meter and diary records in those unaware of this assessment. RESULTS: Eleven observational studies, covering patients with Type 1, Type 2 and gestational diabetes were included spanning 1984-2009. Failure to record blood glucose measurements in the diary was the most extensive 'error', but addition of values, which were not measured, was a greater cause for concern. When present to a high degree, 'errors' lead to decreased variability in diary records compared with meter records. Allowing for a minimal amount of disagreement, just over 50% of adult diaries can be considered as 'accurate/reliable'. Disagreements were most extensive in teenagers and young adults, but the pregnant populations were only slightly better. Agreement was not related to sex, number of insulin injections or duration of monitoring. Those who were younger were more likely to have 'errors', while those who monitored more frequently had more 'accurate' diaries. CONCLUSIONS: The lack of meter-diary agreement suggests that the real reason for monitoring is not understood by many patients, raising issues about motivation, perceived need to impress healthcare providers and denial of poor control. Considering that diaries are used to inform decisions about therapy when HbA1c is raised or in pregnancy, when HbA1c is not suitable, there is significant cause for concern in relation to their clinical utility.
Asunto(s)
Automonitorización de la Glucosa Sanguínea , Glucemia/análisis , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 2/sangre , Diabetes Gestacional/sangre , Registros Electrónicos de Salud , Registros de Salud Personal , Adolescente , Adulto , Factores de Edad , Automonitorización de la Glucosa Sanguínea/instrumentación , Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/terapia , Diabetes Gestacional/terapia , Medicina Basada en la Evidencia , Femenino , Humanos , Hiperglucemia/prevención & control , Hipoglucemia/prevención & control , Masculino , Cooperación del Paciente , EmbarazoRESUMEN
BACKGROUND: Intravesical mesh erosion is an uncommon late complication of placement of a synthetic mid-urethral sling (MUS) for the treatment of stress urinary incontinence, and only a few cases have been reported. Optimal management remains controversial, though there is a tendency toward surgical removal through a variety of routes. However, surgical removal comes with its own risks and is not necessarily associated with an improvement in symptoms. We, herein present the first case of a conservatively managed intravesical mesh erosion following MUS placement. CASE: Nine years after insertion of a tension-free vaginal tape (TVT), a patient presented with persistent lower abdominal pain and dysuria. Flexible cystoscopy demonstrated an erosion of the tape through the bladder wall. The patient declined surgical intervention at the time. Therefore, she was commenced on regular methenamine hippurate and vaginal oestrogen, and kept under surveillance with regular cystoscopies. Her symptoms responded to this treatment and 6 years later remained well controlled on this regime. CONCLUSION: This case demonstrates that conservative management may be a safe and appropriate option for patients who decline surgical excision of mesh erosion.
RESUMEN
BACKGROUND: National guidelines have been developed in the UK to reduce coronary heart disease mortality. This audit assesses provision of lipid analyses by UK Clinical Biochemistry services to support their implementation. METHODS: Audit standards were derived from published guidelines. A questionnaire based on these was circulated to all UK Clinical Biochemistry laboratories. RESULTS: Of 108 replies, routine lipid profiles included triglycerides, HDL-, LDL-cholesterol and total:HDL cholesterol ratio in 98, 85, 72 and 44%, respectively. Only 33% and 27% analysed triglycerides and HDL, respectively, when asked simply to measure cholesterol. Seventy-six percent of the reports stated whether specimens were collected after fasting. For primary prevention, 46% of laboratories stated results should be interpreted in association with other risk factors; 20% referred explicitly to national/local guidelines. Only 19 laboratories quoted secondary prevention treatment thresholds for total cholesterol or LDL-cholesterol. Sixty laboratories occasionally added extra tests and/or interpretive comments. Eight laboratories appeared to provide no input from senior medical/scientific staff into report validation. CONCLUSIONS: These results indicate scope for improvement in the provision of lipid analyses and of information to support their interpretation. We recommend laboratories should routinely provide LDL- and non-HDL-cholesterol results, and that reports should quote treatment thresholds/targets in keeping with current guidelines.
Asunto(s)
Laboratorios/organización & administración , Lípidos/sangre , Guías como Asunto , Humanos , Lípidos/clasificación , Encuestas y Cuestionarios , Reino UnidoRESUMEN
BACKGROUND: Opportunities to improve emergency surgery outcomes exist through guided better practice and reduced variability. Few attempts have been made to define optimal care in emergency surgery, and few clinically derived key performance indicators (KPIs) have been published. A summit was therefore convened to look at resources for optimal care of emergency surgery. The aim of the Donegal Summit was to set a platform in place to develop guidelines and KPIs in emergency surgery. METHODS: The project had multidisciplinary global involvement in producing consensus statements regarding emergency surgery care in key areas, and to assess feasibility of producing KPIs that could be used to monitor process and outcome of care in the future. RESULTS: Forty-four key opinion leaders in emergency surgery, across 7 disciplines from 17 countries, composed evidence-based position papers on 14 key areas of emergency surgery and 112 KPIs in 20 acute conditions or emergency systems. CONCLUSIONS: The summit was successful in achieving position papers and KPIs in emergency surgery. While position papers were limited by non-graded evidence and non-validated KPIs, the process set a foundation for the future advancement of emergency surgery.
Asunto(s)
Lesiones Traumáticas del Encéfalo/cirugía , Pediatría/métodos , Accidentes por Caídas/mortalidad , Accidentes por Caídas/estadística & datos numéricos , Accidentes de Tránsito/mortalidad , Accidentes de Tránsito/estadística & datos numéricos , Adolescente , Mundo Árabe , Lesiones Traumáticas del Encéfalo/epidemiología , Niño , Preescolar , Técnica Delphi , Femenino , Humanos , Lactante , Masculino , Medio Oriente/epidemiología , Pediatría/tendencias , Estudios Retrospectivos , Centros Traumatológicos/organización & administración , Centros Traumatológicos/estadística & datos numéricos , Resultado del TratamientoRESUMEN
The purpose of the present study was to examine if a stable glucose-dependent insulinotropic polypeptide (GIP) agonist could exert beneficial metabolic control in diabetic mice which had been pre-treated with sodium-glucose-cotransporter-2 (SGLT2) inhibitor dapagliflozin (DAPA). High fat fed mice administered low dose streptozotocin (STZ) received vehicle, DAPA once-daily over 28 days, or DAPA once-daily for 14 days followed by (DAla(2))GIP once-daily for 14 days. Energy intake, body weight, glucose and insulin concentrations were measured at regular intervals. Glucose tolerance, insulin tolerance test, dual-energy X-ray absorptiometry (DEXA) and pancreatic histology were examined. Once-daily administration of (DAla(2))GIP for 14 days in high fat fed diabetic mice pre-treated with DAPA demonstrated significant decrease in body weight, blood glucose and increased insulin concentrations which were independent of changes in energy intake. Similarly, glucose tolerance, glucose-stimulated insulin secretion, insulin sensitivity and HOMA-ß were significantly enhanced in (DAla(2))GIP-treated mice. DEXA analysis revealed sustained percentage body fat loss with no changes in lean mass, bone mineral content and density. Pancreatic immunohistochemical analysis revealed decreased islet number and increases in islet area, beta cell area and pancreatic insulin content. The DAPA-induced increase in alpha cell area was also reversed. Additional acute in vitro and in vivo experiments confirmed that the impaired action of (DAla(2))GIP under hyperglycaemic-induced conditions was significantly reversed by DAPA treatment. These data demonstrate that (DAla(2))GIP can exert beneficial metabolic control in high fat fed diabetic mice pre-treated with DAPA. The results highlight possibility of a targeted and personalized approach using a GIP agonist and SGLT2 inhibitor for the treatment of type 2 diabetes.
Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/metabolismo , Polipéptido Inhibidor Gástrico/agonistas , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Animales , Compuestos de Bencidrilo/administración & dosificación , Compuestos de Bencidrilo/farmacología , Compuestos de Bencidrilo/uso terapéutico , Glucemia/metabolismo , Composición Corporal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Diabetes Mellitus Experimental/sangre , Dieta Alta en Grasa , Metabolismo Energético/efectos de los fármacos , Ayuno/sangre , Polipéptido Inhibidor Gástrico/administración & dosificación , Polipéptido Inhibidor Gástrico/farmacología , Polipéptido Inhibidor Gástrico/uso terapéutico , Glucósidos/administración & dosificación , Glucósidos/farmacología , Glucósidos/uso terapéutico , Homeostasis/efectos de los fármacos , Insulina/sangre , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Masculino , Ratones , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transportador 2 de Sodio-Glucosa/genética , Transportador 2 de Sodio-Glucosa/metabolismoRESUMEN
OBJECTIVE: To compare the efficacy of an extended insulin regimen using correction of hyperketonemia as endpoint with a more conventional regimen in the treatment of diabetic ketoacidosis. RESEARCH DESIGN AND METHODS: A total of 22 patients admitted to a Belfast teaching hospital with clinical and biochemical features of diabetic ketoacidosis (pH < 7.25 and/or bicarbonate < 16 mmol/l) were randomized to either conventional or extended insulin regimens. In the conventional regimen, insulin was administered at 5 U/h until near-normoglycemia (blood glucose < or = 10 mmol/l) and then administered at a reduced rate until clinical recovery. In the extended regimen, administration of insulin at 5 U/h was continued beyond attainment of normoglycemia, until resolution of hyperketonemia (3-hydroxybutyrate < 0.5 mmol/l). Main outcome measures were 3-hydroxybutyrate and bicarbonate levels during the 24 h after attainment of near-normoglycemia. RESULTS: After near-normoglycemia, correction of hyperketonemia was achieved earlier with the extended treatment (5.9 +/- 0.8 vs. 21.8 +/- 3.4 h, P = 0.0004 [mean +/- SD]). The area under the curve of 3-hydroxybutyrate against time for 24 h after near-normoglycemia was reduced with the extended treatment (24.9 +/- 3.8 vs. 55.9 +/- 6.7 mmol.l-1.h-1, P = 0.001). These differences remained statistically significant after adjustment for higher baseline levels of 3-hydroxybutyrate at near-normoglycemia in the extended treatment group. Bicarbonate levels at 6 and 12 h after near-normoglycemia were not significantly different between groups. CONCLUSIONS: The extended insulin regimen, which was easy to implement at ward level, produced a more rapid resolution of ketosis than the conventional regimen.
Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Cetoacidosis Diabética/tratamiento farmacológico , Hidroxibutiratos/sangre , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Ácido 3-Hidroxibutírico , Adulto , Bicarbonatos/sangre , Bicarbonatos/metabolismo , Estudios de Cohortes , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/complicaciones , Cetoacidosis Diabética/sangre , Electrólitos/sangre , Electrólitos/metabolismo , Femenino , Humanos , Hipoglucemiantes/administración & dosificación , Inyecciones Intravenosas , Insulina/administración & dosificación , Masculino , Factores de TiempoRESUMEN
Patients with primary biliary cirrhosis (PBC) do not appear to have an increased risk of cardiovascular disease despite elevations in serum cholesterol. Recent evidence has pointed to LpA1 (an apo A1 containing particle which contains apo A1 but not apo A2) in protecting against atherosclerosis. The aim of this study was to investigate apo Al containing particles in the serum of patients with PBC. Lipids and apolipoproteins were measured in 31 patients with PBC (30 females) and 27 control subjects (26 females). Patients were divided into 3 groups: group 1 with bilirubin < 18 micromol/l (n = 17); group 2 with bilirubin > 18 micromol/l (n = 11); and group 3 with end stage liver disease (ESLD, n = 3). As expected group 1 and 2 patients had higher total cholesterol, HDL cholesterol and phospholipids than control subjects. Apo B and apo A1 concentrations were similar to control subjects. However, LpA1 was greatly increased: 0.96 g/l (0.60-1.50), median (range) in group 1 and 1.09 g/l (0.75-1.33) in group 2 versus 0.62 g/l (0.45-0.93) for controls both P < 0.005 and the percentage of total apo A1 in the LpA1 fraction was increased: 54.8% (37.9-63.4) in group 1 and 55.7% (47.8-73.7) in group 2 versus 36.8% (25.1-49.1) for controls, both P < 0.005. Apo A2 concentration was reduced in group 1 0.38 g/l (0.30-0.51) and group 2 0.31 g/l (0.14-0.58) versus controls 0.43 g/l (0.36-0.57), P < 0.05 and P < 0.005 respectively. Patients with ESLD had reduced HDL cholesterol, apo A1, LpA1 and apo A2 compared to controls. These results suggest that PBC is associated with an altered distribution of apo A1 favouring an increased concentration of the protective LpA-I particles. Increased LpA1 concentration may be one of the factors contributing to the paradoxically low incidence of atherosclerosis in PBC patients.
Asunto(s)
Apolipoproteína A-I/sangre , Cirrosis Hepática Biliar/sangre , Adulto , Anciano , Anciano de 80 o más Años , Apolipoproteína A-II/sangre , Apolipoproteínas B/sangre , Arteriosclerosis/etiología , Arteriosclerosis/metabolismo , HDL-Colesterol/sangre , Cromatografía en Gel , Femenino , Humanos , Lípidos/sangre , Cirrosis Hepática Biliar/complicaciones , Cirrosis Hepática Biliar/patología , Fallo Hepático/sangre , Fallo Hepático/complicaciones , Fallo Hepático/patología , Mediciones Luminiscentes , Masculino , Persona de Mediana Edad , Fosfolípidos/sangreRESUMEN
The aim of this study was to develop a mutation screening protocol for familial hypercholesterolaemia (FH) patients and to assess genotype/phenotype effects in terms of pre-treatment lipid profiles and presentation of tendon xanthomata (TX). A total of 158 families with clinical definitions of possible (120) or definite (38) FH were studied using a tiered screening protocol. Mutations were identified in 52 families, 44 families showing 23 different LDLR gene defects and eight families showing the common Apo B100 gene defect R3500Q. LDLR defects were detected in various regions of the gene with 56% in the LDL binding domain (exons 2-6) and 37% in the EGF precursor homology domain (exons 7-14). The most common mutations were D461N(7), C210X(5), 932delA(5), and C163Y(4). Frameshift mutations accounted for 20% with nonsense 13%, mis-sense 35%, splice 3%, Apo B 13% and 2% large deletion, 13% of clinically definite FH remained undefined. In conclusion, DNA based diagnosis is possible in 79% (30/38) of clinically definite FH families and of the 120 possible FH families at the start of the screening program, 18% (22/120) now have defined mutations. Overall 60 families from the original 158 meet the clinical and/or genetic criteria for definite FH. Tendon xanthomata were present in only 58% (30/52) of genetically defined FH families, thus limiting its use as a strict diagnostic criteria. Families with low density lipoprotein receptor (LDLR) defects present with higher total and LDL cholesterol levels and a higher incidence of TX than do those with the common Apo B variant, and frameshift mutations appear to have the most severe presentation.
Asunto(s)
Pruebas Genéticas/métodos , Hiperlipoproteinemia Tipo II/genética , Mutación Puntual/genética , Electroforesis en Gel de Agar , Femenino , Genética de Población , Genotipo , Humanos , Masculino , Tamizaje Masivo/métodos , Fenotipo , Regiones Promotoras Genéticas , Sensibilidad y EspecificidadRESUMEN
A single base deletion (211delG) in the low density lipoprotein receptor (LDLR) gene was shown to cause familial hypercholesterolaemia (FH) in a large family from Northern Ireland. Twenty-four of 52 family members tested had this mutation, 13 of which were newly diagnosed. Mutation-positive individuals had significantly higher mean total-cholesterol (TC) and LDL-cholesterol (LDL-C) than those without 211delG. LDL-C was a more accurate indicator of disease status than TC. When TC levels alone were considered, in individuals over 16 years, a false negative rate (TC < 7.5 mmol/l) of 40% was found; however this fell to 13% based on inclusion of LDL-C levels. Individuals with coronary artery disease (CAD) had significantly higher TC levels than those without CAD and tended to have tendinous xanthomas (TX) and corneal arcus (CA). Generic polymorphisms in the angiotensin converting enzyme (ACE) and apolipoprotein (apo) B genes did not appear to be associated with lipid levels or with the clinical severity of the disease; however, the apo E epsilon4 allele did show a lipid-raising effect in individuals with the mutation.
Asunto(s)
Apolipoproteínas B/genética , Apolipoproteínas E/genética , Hiperlipoproteinemia Tipo II/genética , Lípidos/sangre , Peptidil-Dipeptidasa A/genética , Mutación Puntual , Polimorfismo Genético , Receptores de LDL/genética , Eliminación de Secuencia , Adolescente , Adulto , Anciano , Arco Senil/epidemiología , Arco Senil/genética , Secuencia de Bases , Niño , Preescolar , Colesterol/sangre , Femenino , Humanos , Hiperlipoproteinemia Tipo II/sangre , Lactante , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Irlanda del Norte/epidemiología , Linaje , Xantomatosis/epidemiología , Xantomatosis/genéticaRESUMEN
We report a rare apolipoprotein E variant in an Irish female with Type III hyperlipidaemia who has the phenotype E2E1 as determined by isoelectric focusing. Sequence analysis of the apolipoprotein E gene from the proband and from four other family members, using DNA amplified by the polymerase chain reaction, demonstrated the presence of a point mutation in the common epsilon 2 allele with a G-->A transition at nucleotide 3791. This was confirmed by digestion with the restriction endonuclease TaqI, which cuts at a new site within the apolipoprotein E gene, created by the base change. This mutation results in a substitution of aspartic acid for glycine at position 127 of the mature protein. We believe this to be the first description of this apolipoprotein E variant in a family from the British Isles. The mutation appears to be 'recessive' with respect to the expression of Type III hyperlipidaemia, although it may be somewhat more potent in this regard than the parent epsilon 2 allele. The Type III hyperlipidaemia is responsive to treatment with diet and gemfibrozil.